Bal Pharma Q1 profit jumps 259 percent, Philippines JV, promoter warrants

Management Changes View source PDF Explain this filing

BALPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹90.03

prior close

₹88.25

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-2.4% vs market

Pharmaceuticals peers, median of 166sector+0.1%-2.4% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3+0.2-2.4+0.1-2.4

Next day

-3.1+0.2-3.3-0.2-2.9

-5.6+0.4-5.9-0.2-5.4

-5.0+0.7-5.8-0.1-4.9

-5.4+0.1-5.6-1.4-4.0

-4.6+0.7-5.2-0.8-3.8

-5.6+1.2-6.8-0.5-5.1

15d

-1.5+0.7-2.2+0.3-1.8

+19.4-1.2+20.6-0.2+19.6

+8.9-1.1+10.0-2.4+11.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone Q1 revenue rose to Rs 88.43 cr from Rs 65.64 cr YoY, net profit to Rs 1.16 cr from Rs 0.32 cr. Consolidated revenue Rs 88.61 cr, net profit Rs 1.14 cr. Board approved investing up to Rs 9 cr in a 65 percent JV in the Philippines for pharma distribution, with Hemera Holdings holding 35 percent. Allotted 10 lakh warrants at Rs 84 each (Rs 8.4 cr total) to promoter Shailesh Siroya, with 25 percent already paid. Two directors swapped designations. Auditors gave unmodified opinion.

Likely market impact

Strong revenue and profit growth. Philippines JV adds new geography. Promoter warrant allotment may dilute equity by about 6 percent upon conversion.